I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Sehn, L. H.
326
results:
Online X
Search for persons
X
Format
Online (326)
Mediatypes
Articles (Online) (172)
Bookchapter (Online) (1)
OpenAccess-fulltext (153)
Languages
english (310)
german (3)
Sorted by: Relevance
Sorted by: Year
?
1
Subgroup analysis of elderly patients (pts) with diffuse la..:
Hu, B.
;
Reagan, P. M.
;
Sehn, L. H.
...
Hematological Oncology. 41 (2023) S2 - p. 416-418 , 2023
Link:
https://doi.org/10.1002/..
?
2
Tafasitamab plus lenalidomide versus standard of care as se..:
Sehn, L. H.
;
Kuruvilla, J.
;
Salles, G.
...
Hematological Oncology. 41 (2023) S2 - p. 441-442 , 2023
Link:
https://doi.org/10.1002/..
?
3
PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R..:
Sehn, L. H
;
Chamuleau, M.
;
Lenz, G.
...
Hematological Oncology. 41 (2023) S2 - p. 849-850 , 2023
Link:
https://doi.org/10.1002/..
?
4
Impact of the Dark Zone Signature on Central Nervous System..:
Alduaij, W.
;
Jiang, A.
;
Collinge, B.
...
Hematological Oncology. 41 (2023) S2 - p. 294-296 , 2023
Link:
https://doi.org/10.1002/..
?
5
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WI..:
Sehn, L. H.
;
Bartlett, N. L.
;
Matasar, M.
...
Hematological Oncology. 41 (2023) S2 - p. 122-125 , 2023
Link:
https://doi.org/10.1002/..
?
6
CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES ..:
Herrera, A. F.
;
Tracy, S.
;
Sehn, L. H.
...
Hematological Oncology. 41 (2023) S2 - p. 175-177 , 2023
Link:
https://doi.org/10.1002/..
?
7
Analysis of Real‐World Treatment Patterns and Outcomes Amon..:
Sehn, L. H.
;
Wang, A.
;
Yu, J.
...
Hematological Oncology. 41 (2023) S2 - p. 373-375 , 2023
Link:
https://doi.org/10.1002/..
?
8
P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN P..:
Matasar, M.
;
Bartlett, N. L.
;
Sehn, L. H.
...
HemaSphere. 6 (2022) - p. 1016-1017 , 2022
Link:
https://doi.org/10.1097/..
?
9
P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMEN..:
Morschhauser, F.
;
Jiang, Y.
;
Jardin, F.
...
HemaSphere. 6 (2022) - p. 1076-1077 , 2022
Link:
https://doi.org/10.1097/..
?
10
PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUB..:
Sehn, L. H.
;
Avivi, I.
;
Brody, J.
...
HemaSphere. 6 (2022) - p. 2004-2005 , 2022
Link:
https://doi.org/10.1097/..
?
11
P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDO..:
Sehn, L. H.
;
Hübel, K.
;
Luminari, S.
...
HemaSphere. 6 (2022) - p. 993-994 , 2022
Link:
https://doi.org/10.1097/..
?
12
THE TOPOLOGY OF MYC REARRANGEMENTS IN DOUBLE‐HIT LYMPHOMA I..:
Hilton, L. K.
;
Collinge, B.
;
Ben‐Neriah, S.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
13
RITUXIMAB IN COMBINATION WITH BENDAMUSTINE OR HIGH‐DOSE CYT..:
Villa, D.
;
Hoster, E.
;
Hermine, O.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
14
WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLB..:
Hilton, L. K
;
Collinge, B
;
Rushton, C. K
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
15
INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND R..:
Hübel, K.
;
Scholz, C. W.
;
Luminari, S.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
1-15